JP2025507830A5 - - Google Patents
Info
- Publication number
- JP2025507830A5 JP2025507830A5 JP2024551929A JP2024551929A JP2025507830A5 JP 2025507830 A5 JP2025507830 A5 JP 2025507830A5 JP 2024551929 A JP2024551929 A JP 2024551929A JP 2024551929 A JP2024551929 A JP 2024551929A JP 2025507830 A5 JP2025507830 A5 JP 2025507830A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- iptacopan
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263316623P | 2022-03-04 | 2022-03-04 | |
| US63/316,623 | 2022-03-04 | ||
| PCT/IB2023/052010 WO2023166487A1 (en) | 2022-03-04 | 2023-03-03 | Use of iptacopan for the treatment of lupus nephritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025507830A JP2025507830A (ja) | 2025-03-21 |
| JP2025507830A5 true JP2025507830A5 (https=) | 2026-02-04 |
Family
ID=85704041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024551929A Pending JP2025507830A (ja) | 2022-03-04 | 2023-03-03 | ループス腎炎の処置のためのイプタコパンの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250195492A1 (https=) |
| EP (1) | EP4486343A1 (https=) |
| JP (1) | JP2025507830A (https=) |
| KR (1) | KR20240155291A (https=) |
| CN (1) | CN118785906A (https=) |
| AU (1) | AU2023229221A1 (https=) |
| CA (1) | CA3248808A1 (https=) |
| IL (1) | IL314494A (https=) |
| MX (1) | MX2024010644A (https=) |
| WO (1) | WO2023166487A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119656165A (zh) * | 2023-09-20 | 2025-03-21 | 上海美悦生物科技发展有限公司 | 杂环化合物在制备预防和/或治疗肾脏疾病的药物中的用途 |
| US20250161347A1 (en) | 2023-11-22 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Methods and compositions for treating non-alcoholic fatty liver disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG183512A1 (en) * | 2010-03-03 | 2012-09-27 | Teva Pharma | Treatment of lupus nephritis using laquinimod |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| CN120208923A (zh) | 2020-05-18 | 2025-06-27 | 诺华股份有限公司 | Lnp023的结晶形式 |
-
2023
- 2023-03-03 IL IL314494A patent/IL314494A/en unknown
- 2023-03-03 KR KR1020247031773A patent/KR20240155291A/ko active Pending
- 2023-03-03 MX MX2024010644A patent/MX2024010644A/es unknown
- 2023-03-03 JP JP2024551929A patent/JP2025507830A/ja active Pending
- 2023-03-03 WO PCT/IB2023/052010 patent/WO2023166487A1/en not_active Ceased
- 2023-03-03 CN CN202380023870.8A patent/CN118785906A/zh active Pending
- 2023-03-03 AU AU2023229221A patent/AU2023229221A1/en active Pending
- 2023-03-03 CA CA3248808A patent/CA3248808A1/en active Pending
- 2023-03-03 EP EP23711786.6A patent/EP4486343A1/en active Pending
- 2023-03-03 US US18/843,599 patent/US20250195492A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3032996C (en) | FORMULATION FOR THE INHIBITION OF 5-HT2B AGONISTS AND METHODS FOR THEIR USE | |
| CA2367605A1 (en) | Apomorphine and sildenafil composition | |
| JP2002541097A (ja) | 線維筋痛症及び関連症状の治療におけるフルピルチン | |
| KR19990082429A (ko) | 장염 질환을 치료하기 위한 니코틴의 결장 전달 | |
| TW201210593A (en) | Compositions and methods for treating centrally mediated nausea and vomiting | |
| KR20120101456A (ko) | 중추 매개의 오심 및 구토를 치료하기 위한 조성물 및 방법 | |
| JP2025507830A5 (https=) | ||
| JP2002524498A (ja) | 機能性及び／又は器質性痛み症候群の治療のための製薬組成物の調製のためのアセチルコリンエステラーゼ阻害剤の使用 | |
| WO2008002514A2 (en) | Combination cough treatment compounds and method of treating common coughs | |
| JP2016074728A (ja) | 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用 | |
| JPS59193821A (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP2024515885A5 (https=) | ||
| TW201828937A (zh) | 供治療重症肌無力及其他肌無力症候群之用途及組合物 | |
| Davis et al. | Comparative morphine pharmacokinetics following sublingual, intramuscular, and oral administration in patients with cancer | |
| TW202308653A (zh) | 以神經活性類固醇進行治療的方法 | |
| US20200030319A1 (en) | Dosing Regimens for Fast Onset of Antidepressant Effect | |
| JP2021530568A5 (https=) | ||
| CN107519176A (zh) | 防治运动病、梅尼埃病的药物及莫扎伐普坦的医药用途 | |
| KR20120104574A (ko) | 티보자닙과 템시롤리무스의 조합물 | |
| RU2024128433A (ru) | Применение иптакопана для лечения волчаночного нефрита | |
| US20060079513A1 (en) | Methods and compositions including methscopolamine nitrate | |
| WO2025184490A1 (en) | N-[4-fluor-5-[[(2s, 4 r)-4-[(6-methoxy-4-pyrimidinyl)oxy]- 2-methyl-1-pyrrolidinyl] methyl ]-2-thiazolyl]acetamid for use in the treatment of alzheimer disease | |
| CN108478581A (zh) | 防治运动病、梅尼埃病的药物及托伐普坦的医药用途 | |
| WO2019023175A1 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA | |
| JP2023507764A5 (https=) |